Sung Eun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sung Eun Kim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Jeong Eun Lee
Department of Radiation Oncology School of Medicine Kyungpook National University Daegu South Korea
2 shared publicationsJi Yoon Kim
2 shared publications- Ye Jee Shim
Department of Pediatrics, School of Medicine Kyungpook National University Daegu Korea
2 shared publications - Young Shil Park
Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea
2 shared publications - Bo Ram Kim
Division of Pediatric Hemato-Oncology, Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea
1 shared publication Chuhl Joo Lyu
Department of Pediatrics, Yonsei University Severance Children’s Hospital, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Thrombosis Research
- Vol. 266
Real-world effectiveness of emicizumab prophylaxis in Korean patients with severe hemophilia A
- 4 November 2026
- Published by Elsevier in Thrombosis Research
- Vol. 266
Open AccessReal-world effectiveness of emicizumab prophylaxis in Korean patients with severe hemophilia A
- Open Access
- 29 October 2026
- Published by Wiley in Pediatric Blood & Cancer
Lorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report
Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN ‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia. Lorlatinib‐containing chemotherapy resulted in near‐complete resolution of leptomeningeal disease and full neurologic recovery. Although subsequent CNS recurrence was confirmed and ultimately prompted CSI, the initial response permitted its deferral for 11 months. This case highlights the potential of lorlatinib‐containing therapy to reduce CNS tumor burden and serve as a bridging strategy to CSI despite concurrent MYCN amplification.
- 29 October 2026
- Published by Wiley in Pediatric Blood & Cancer
Open AccessLorlatinib‐Containing Therapy for MYCN ‐Amplified, ALK ‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report
Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN ‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia. Lorlatinib‐containing chemotherapy resulted in near‐complete resolution of leptomeningeal disease and full neurologic recovery. Although subsequent CNS recurrence was confirmed and ultimately prompted CSI, the initial response permitted its deferral for 11 months. This case highlights the potential of lorlatinib‐containing therapy to reduce CNS tumor burden and serve as a bridging strategy to CSI despite concurrent MYCN amplification.
- Open Access
- 18 October 2024
- Published by Springer Nature in Blood Research
- Vol. 59 (1) , 1-6
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Purpose: Hemophilia A is a genetic disorder characterized by a lack of factor VIII (FVIII). Emicizumab, a recombinant humanized bispecific monoclonal antibody, mimics the function of FVIII. In this article, we present data on an initial real-world evaluation of emicizumab use in Korean children with severe hemophilia A without inhibitors. Methods: This study was conducted from June 2020 to March 2024 at 4 centers in Korea. The participants were pediatric patients with severe hemophilia A without inhibitors who had received emicizumab treatment for over 6 months. The mean and median annualized bleeding rates (ABRs) and mean and median annual joint bleeding rates (AJBRs) were compared. Results: Each of the 21 patients in the study received an emicizumab loading regimen of 3 mg/kg weekly for 4 weeks, followed by a modified maintenance regimen of which 2 patients (9.5%) received a 1.5 mg/kg weekly dose, 3 patients (14.3%) received a 6 mg/kg dose every 4 weeks, and the remaining 16 patients (76.2%) received a 3 mg/kg dose every 2 weeks. Before emicizumab prophylaxis initiation, the mean and median ABRs for all patients were 7.04 (SD ± 5.83) and 6.52 (range 0–21.74), respectively. After receiving emicizumab treatment, the mean and mediam ABRs decreased to 0.41 and zero, respectively. Additionally, 85.7% of the patients achieved no bleeding events within 6 months of starting the treatment. Conclusion: These first real-world data in Korea indicate that emicizumab is effective and safe for pediatric patients with severe hemophilia A without inhibitors.
- 18 October 2024
- Published by Springer Nature in Blood Research
- Vol. 59 (1) , 1-6
Open AccessReal-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Purpose: Hemophilia A is a genetic disorder characterized by a lack of factor VIII (FVIII). Emicizumab, a recombinant humanized bispecific monoclonal antibody, mimics the function of FVIII. In this article, we present data on an initial real-world evaluation of emicizumab use in Korean children with severe hemophilia A without inhibitors. Methods: This study was conducted from June 2020 to March 2024 at 4 centers in Korea. The participants were pediatric patients with severe hemophilia A without inhibitors who had received emicizumab treatment for over 6 months. The mean and median annualized bleeding rates (ABRs) and mean and median annual joint bleeding rates (AJBRs) were compared. Results: Each of the 21 patients in the study received an emicizumab loading regimen of 3 mg/kg weekly for 4 weeks, followed by a modified maintenance regimen of which 2 patients (9.5%) received a 1.5 mg/kg weekly dose, 3 patients (14.3%) received a 6 mg/kg dose every 4 weeks, and the remaining 16 patients (76.2%) received a 3 mg/kg dose every 2 weeks. Before emicizumab prophylaxis initiation, the mean and median ABRs for all patients were 7.04 (SD ± 5.83) and 6.52 (range 0–21.74), respectively. After receiving emicizumab treatment, the mean and mediam ABRs decreased to 0.41 and zero, respectively. Additionally, 85.7% of the patients achieved no bleeding events within 6 months of starting the treatment. Conclusion: These first real-world data in Korea indicate that emicizumab is effective and safe for pediatric patients with severe hemophilia A without inhibitors.
- Open Access
- 31 October 2023
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 30 (2) , 103-104
Radiotherapy for Childhood Cancer
Sung Eun Kim and Jeong Eun Lee. CPHO 2023;30:103-4. https://doi.org/10.15264/cpho.2023.30.2.103
- 31 October 2023
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 30 (2) , 103-104
Open AccessRadiotherapy for Childhood Cancer
Sung Eun Kim and Jeong Eun Lee. CPHO 2023;30:103-4. https://doi.org/10.15264/cpho.2023.30.2.103